We have aimed to demonstrate the impact of TGF-β1 and fluvastatin on human breast cancer (MCF-7) and human hepatocellular carcinoma (Hep3B) cell cultures via Real-Time Cell Analyzer (RTCA) and to test the expression levels of some genes (NDRG1, SGK1, TWIST1, AMPKA2) and to compare their gene expression levels according to RTCA results.
β2M has a different molecular regulatory mechanism between ER<sup>+</sup> and ER<sup>-</sup> breast cancer with HER2<sup>-</sup>, and it may promote tumor survival through the SGK1/Bcl-2 signaling pathway in ER<sup>+</sup> breast cancer with HER2<sup>-</sup> and has no regulatory effects on ER<sup>-</sup> breast cancer with HER2<sup>-</sup>.
Subsequently, the Oncomine and the OncoLnc database were employed to verify the differential expression and the association with clinical outcome of SGK1 gene in breast cancer patients.
SGK1 may act as a downstream intracellular regulator of c-fms, particularly of c-fms-induced adhesiveness of breast cancer cells after exposure to GC or CSF-1.